Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Clinical Genitourinary Cancer|June 6, 2017
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421Guru Sonpavde, Gregory R Pond, Melissa Plets, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 21, 2022
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)Neeraj Agarwal, Catherine M Tangen, Maha H A Hussain, et al.The New England Journal of Medicine|November 26, 2024
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder CancerSeth P Lerner, Catherine Tangen, Robert S Svatek, et al.Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell CarcinomaPedro Barata, Catherine Tangen, Melissa Plets, et al.JAMA|May 26, 2018
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical TrialEdward M Messing, Catherine M Tangen, Seth P Lerner, et al.European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip P Patel, Megan Othus, Young Kwang Chae, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2021
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)Amir Goldkorn, Catherine Tangen, Melissa Plets, et al.European Urology|May 22, 2025
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder CancerMarie-Pier St-Laurent, Parminder Singh, David J McConkey, et al.Pageof 4